Compositions and methods for treating, ameliorating and preventing h. pylori infections
A Helicobacter pylori, individual technology, applied in the field of infectious diseases and drugs, can solve problems such as rising clarithromycin resistance
Pending Publication Date: 2019-10-22
CENT FOR DIGESTIVE DISEASES PTY LTD
View PDF17 Cites 6 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
However, rising resistance to clarithromycin has terminated the clinical use of this combination in many parts of the world
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment
[0554] A 47-year-old man, allergic to penicillin, was referred after five different therapies had failed to eradicate H. pylori and he remained symptomatic. To better improve eradication and biofilm dissolution, he pretreated with Bifidobacterium infantum three times a day for 4 weeks, and this was continued during antibiotic treatment for the next 10 days. Antibiotic therapy included [all × 3 per day] vonoprazan 20 mg; metronidazole 400 mg; bismuth subsalicylate 300 mg; tetracycline HCl 400 mg; When retested by urea breath test 4 weeks after discontinuation of treatment, the test was negative, showing bacterial eradication.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
Provided are methods for treating, ameliorating, reversing and / or preventing a Helicobacter pylori (H. pylori) infection in an individual in need thereof, comprising: administering to the individual in need thereof a therapeutic combination comprising: (a) a composition comprising or consisting of: vonoprazan or a vonoprazan fumarate, or a 5- (2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine monofumarate, or a 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methyl-methanamine fumarate), optionally TAKECABTM; and (b) an antimicrobial or antibiotic drug or composition.
Description
technical field [0001] The present invention relates generally to infectious diseases and medicines. In an alternative embodiment, there is provided a combination of therapeutic agents for treating, alleviating, reversing and / or preventing (as prophylaxis) Helicobacter pylori (H. pylori) infection in an individual in need thereof, the combination comprising manufactured Products and kits and methods. Background technique [0002] The history of H. pylori eradication dates back to 1984 when the first triple therapy was developed in Australia by Borody of the Center for Digestive Diseases. It consists of bismuth, tetracycline, and metronidazole. Its long-term effects were reported in 1989, and it was dispensed to patients on prescriptions written by most physicians in combination as a single prescription until a commercial product known as Helidac became available in several countries. Since then, a number of triple therapies have been described, the most common of which is...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K31/4439A61K31/43A61K31/7048A61K31/4164A61K31/438A61K31/5383A61K31/496A61K31/4725A61K31/24A61K31/422A61K31/65A61K31/29A61K31/04A61P1/04
CPCA61P31/04A61K31/43A61K31/4164A61K31/65A61K31/454A61K31/60A61K31/4439A61K33/245A61K35/745A61K2300/00A61K31/7048A61K31/5383A61K31/4709A61K31/4178A61K31/422A61K31/438A61P1/04A61K31/426A61K31/424A61K33/00
Inventor 托马斯·朱利叶斯·波洛迪
Owner CENT FOR DIGESTIVE DISEASES PTY LTD



